{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:42:36Z","timestamp":1792604556433,"version":"4.5.0"},"reference-count":46,"publisher":"Department of Medicine, Warren Alpert Medical School at Brown University","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Sodium-glucose cotransporter 2 (SGLT2) inhibitors were initially developed as oral hypoglycemic agents for type 2 diabetes (T2D), but mounting evidence has solidified their role as practice-changing therapies for cardiovascular-kidney-metabolic (CKM) syndrome, which includes congestive heart failure (CHF) and chronic kidney disease (CKD). This review summarizes the pivotal randomized controlled trials evaluating SGLT2 inhibitors, highlighting their clinical efficacy, key mechanisms of action, and adverse effects. As indications continue to expand and more patients are prescribed SGLT2 inhibitors, hospitalists must have a thorough understanding of this important medication class.<\/jats:p>","DOI":"10.56305\/001c.171893","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:56:00Z","timestamp":1791809760000},"source":"Crossref","is-referenced-by-count":0,"title":["Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of Current Evidence, Mechanisms, and Adverse Effects"],"prefix":"10.56305","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2070-497X","authenticated-orcid":true,"given":"Samuel D","family":"Woodworth","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/034c1gc25","id-type":"ROR","asserted-by":"publisher"}],"name":"Maine Medical Center","department":["Department of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hayden","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/034c1gc25","id-type":"ROR","asserted-by":"publisher"}],"name":"Maine Medical Center","department":["Department of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"35509","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"S. D. Solomon","year":"2022","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"ref2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial","volume":"143","author":"M. Packer","year":"2021","journal-title":"Circulation"},{"issue":"12","key":"ref3","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1001\/jamacardio.2022.3750","article-title":"Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial","volume":"7","author":"M. Vaduganathan","year":"2022","journal-title":"The Journal of the American Medical Association Cardiology"},{"issue":"13","key":"ref4","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1161\/CIRCULATIONAHA.123.065748","article-title":"Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure","volume":"148","author":"M. Packer","year":"2023","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"A. A. Voors","year":"2022","journal-title":"Nature Medicine"},{"issue":"20","key":"ref6","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1161\/CIRCULATIONAHA.125.076575","article-title":"Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure","volume":"152","author":"D. D. Berg","year":"2025","journal-title":"Circulation"},{"issue":"24","key":"ref7","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"V. Perkovic","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"15","key":"ref8","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"H. J. L. Heerspink","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"ref9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"W. G. Herrington","year":"2023","journal-title":"The New England Journal of Medicine"},{"issue":"9","key":"ref10","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/ndt\/gfaf046","article-title":"Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease","volume":"40","author":"W. M. Bakker","year":"2025","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 2","key":"ref11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.6002\/ect.IAHNCongress.25","article-title":"A Story of Serendipities: From Phlorizin to Gliflozins","volume":"21","author":"\u00d6. Helvac\u0131","year":"2023","journal-title":"Experimental and Clinical Transplantation: Official Journal of the Middle East Society for Organ Transplantation"},{"issue":"12","key":"ref12","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/s41574-025-01170-4","article-title":"Cardiometabolic and renal benefits of sodium-glucose cotransporter 2 inhibitors","volume":"21","author":"Y. H. Lee","year":"2025","journal-title":"Nature Reviews Endocrinology"},{"issue":"1","key":"ref13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","volume":"94","author":"H. J. L. Heerspink","year":"2018","journal-title":"Kidney International"},{"issue":"2","key":"ref14","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/jcp.30621","article-title":"Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease","volume":"237","author":"S. Ravindran","year":"2022","journal-title":"Journal of Cellular Physiology"},{"issue":"1","key":"ref15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2337\/db24-0406","article-title":"Effect of Hyperketonemia on Myocardial Function in Patients With Heart Failure and Type 2 Diabetes","volume":"74","author":"C. Solis-Herrera","year":"2025","journal-title":"Diabetes"},{"issue":"8","key":"ref16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41581-024-00836-y","article-title":"Applications of SGLT2 inhibitors beyond glycaemic control","volume":"20","author":"D. V. O'Hara","year":"2024","journal-title":"Nature Reviews Nephrology"},{"issue":"4","key":"ref17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2215\/CJN.0000000000000362","article-title":"Alleviation of Anemia by SGLT2 Inhibitors in Patients with CKD: Mechanisms and Results of Long-Term Placebo-Controlled Trials","volume":"19","author":"M. Packer","year":"2023","journal-title":"Clinical Journal of the American Society of Nephrology"},{"issue":"6","key":"ref18","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/dom.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"C. J. Bailey","year":"2019","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"6","key":"ref19","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamainternmed.2024.0376","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin","volume":"184","author":"N. McCormick","year":"2024","journal-title":"The Journal of the American Medical Association Internal Medicine"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e080035","DOI":"10.1136\/bmj-2024-080035","article-title":"Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies","volume":"387","author":"N. McCormick","year":"2024","journal-title":"The BMJ"},{"issue":"7","key":"ref21","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamainternmed.2025.0686","article-title":"SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors","volume":"185","author":"S. Wing","year":"2025","journal-title":"The Journal of the American Medical Association Internal Medicine"},{"issue":"6146","key":"ref22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/330379a0","article-title":"Expression cloning and cDNA sequencing of the Na+\/glucose co-transporter","volume":"330","author":"M. A. Hediger","year":"1987","journal-title":"Nature"},{"issue":"4","key":"ref23","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review","volume":"7","author":"A. Mantovani","year":"2022","journal-title":"Lancet Gastroenterology and Hepatology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e083735","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial","volume":"389","author":"J. Lin","year":"2025","journal-title":"The BMJ"},{"issue":"11","key":"ref25","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2337\/dc17-1011","article-title":"Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis","volume":"40","author":"G. N. Nadkarni","year":"2017","journal-title":"Diabetes Care"},{"issue":"10365","key":"ref26","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"ref27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2025.20834","article-title":"SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis","volume":"335","author":"B. L. Neuen","year":"2026","journal-title":"The Journal of the American Medical Association"},{"issue":"9","key":"ref28","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2026.9268","article-title":"Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial","volume":"336","author":"M. J. P. Oosterom-Eijmael","year":"2026","journal-title":"The Journal of the American Medical Association"},{"issue":"5","key":"ref29","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/metabo14050264","article-title":"Ketoacidosis and SGLT2 Inhibitors: A Narrative Review","volume":"14","author":"C. Morace","year":"2024","journal-title":"Metabolites"},{"issue":"24","key":"ref30","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1056\/NEJMe1711296","article-title":"Adjunctive Treatments for Type 1 Diabetes","volume":"377","author":"D. M. Nathan","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"9","key":"ref31","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition","volume":"38","author":"A. L. Peters","year":"2015","journal-title":"Diabetes Care"},{"issue":"6","key":"ref32","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2337\/dc23-1129","article-title":"Association of Continued Use of SGLT2 Inhibitors From the Ambulatory to Inpatient Setting With Hospital Outcomes in Patients With Diabetes: A Nationwide Cohort Study","volume":"47","author":"L. G. Singh","year":"2024","journal-title":"Diabetes Care"},{"key":"ref33","article-title":"Guidance for Industry on Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes","author":"U.S. Food and Drug Administration","year":"2008"},{"issue":"2","key":"ref34","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s12020-025-04393-7","article-title":"Risk of genitourinary tract infections with SGLT-2 inhibitors in type 2 diabetes mellitus: A meta-analysis of randomised controlled trials and disproportionality analysis using FAERS","volume":"90","author":"B. T. Yoosuf","year":"2025","journal-title":"Endocrine"},{"issue":"suppl 1","key":"ref35","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2337\/db19-1224-P","article-title":"1224-P: Improving compliance with SGLT2 inhibitors by reducing the risk of genital mycotic infections: the outcomes of personal hygiene advice","volume":"68","author":"S. M. Williams","year":"2019","journal-title":"Diabetes"},{"issue":"11","key":"ref36","doi-asserted-by":"publisher","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases","volume":"170","author":"S. J. Bersoff-Matcha","year":"2019","journal-title":"Annals of Internal Medicine"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf788","article-title":"Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients","author":"M. Z. Wu","year":"2025","journal-title":"European Heart Journal"},{"issue":"1","key":"ref38","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus","volume":"101","author":"N. B. Watts","year":"2016","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"12","key":"ref39","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/dom.12742","article-title":"Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials","volume":"18","author":"H. L. Tang","year":"2016","journal-title":"Diabetes, Obesity, and Metabolism"},{"issue":"Supplement_1","key":"ref40","doi-asserted-by":"publisher","first-page":"S339","DOI":"10.2337\/dc26-S016","article-title":"16. Diabetes care in the hospital: Standards of care in diabetes\u20142026","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2025","journal-title":"Diabetes Care"},{"issue":"22","key":"ref41","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"B. Zinman","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"ref42","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"B. Neal","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"ref43","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"S. D. Wiviott","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"21","key":"ref44","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"J. J. V. McMurray","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"15","key":"ref45","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"M. Packer","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"16","key":"ref46","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"S. D. Anker","year":"2021","journal-title":"The New England Journal of Medicine"}],"container-title":["Journal of Brown Hospital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bhm.scholasticahq.com\/article\/171893-sodium-glucose-cotransporter-2-inhibitors-a-scoping-review-of-current-evidence-mechanisms-and-adverse-effects","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:23:27Z","timestamp":1792603407000},"score":1,"resource":{"primary":{"URL":"https:\/\/bhm.scholasticahq.com\/article\/171893-sodium-glucose-cotransporter-2-inhibitors-a-scoping-review-of-current-evidence-mechanisms-and-adverse-effects"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.56305\/001c.171893","relation":{},"ISSN":["2994-5593"],"issn-type":[{"value":"2994-5593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}